XML 19 R7.htm IDEA: XBRL DOCUMENT v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Operating activities:          
Net (loss) income $ (4,847) $ 18,886 $ (35) $ 27,865  
Adjustments to reconcile net (loss) income to net cash provided by operating activities:          
Deferred taxes     2,149 15,998  
Depreciation of fixed assets and amortization of intangible assets     48,490 37,289  
Amortization of debt issuance costs 849 763 1,694 1,444  
Amortization of debt discount 23 23 45 47  
Gain on early extinguishment of debt 0 7,518 0 7,518  
Stock-based compensation     30,025 25,675  
Changes in contingent consideration     (3,032) (2,297)  
Impairment of investment     11,000 0  
Other net (gains) losses     (5,887) 109  
Changes in operating assets and liabilities:          
Accounts receivable, net     (1,046) 776  
Inventories, net     (22,871) 915  
Prepaid expenses and other assets     (18,635) (1,309)  
Accounts payable     9,344 2,772  
Accrued expenses and income taxes payable     (14,675) 1,361  
Other liabilities     10,905 (790)  
Net cash provided by operating activities     47,471 102,337  
Investing activities:          
Acquisition of GQ Bio Therapeutics GmbH (net of cash acquired)     (16,702) 0  
Purchases of fixed assets     (11,245) (4,426)  
Purchases of available-for-sale investments     (74,685) (105,781)  
Sales of available-for-sale investments     140,416 79,462  
Purchases of debt investments     (1,250) 0  
Net cash provided by (used in) investing activities     36,534 (30,745)  
Financing activities:          
Proceeds from shares issued under employee stock purchase plan     1,569 1,364  
Payment of employee withholding taxes on restricted stock unit vests     (5,466) (382)  
Purchase of treasury stock, inclusive of broker fees     (50,039) (25,000)  
Proceeds from 2029 convertible senior notes     0 287,500  
Purchase of capped call transactions     0 (26,709)  
Payment of debt issuance and financing costs     0 (9,350)  
Net cash (used in) provided by financing activities     (60,499) 22,163  
Effect of exchange rate changes on cash and cash equivalents     204 0  
Net increase in cash and cash equivalents     23,710 93,755  
Cash and cash equivalents, beginning of period     276,774 153,298 $ 153,298
Cash and cash equivalents, end of period 300,484 247,053 300,484 247,053 $ 276,774
Supplemental cash flow information:          
Cash paid for interest     7,687 6,988  
Net cash paid for income taxes     8,233 4,667  
Non-cash investing and financing activities:          
Fixed assets included in accounts payable and accrued liabilities     1,431 604  
Excise tax on share repurchases included in accrued liabilities $ 354 $ 121 354 121  
3.375% Convertible senior notes due May 2024          
Financing activities:          
Payment of debt     0 (8,641)  
0.750% Convertible senior notes due August 2025          
Financing activities:          
Payment of debt     0 (190,994)  
Term Loan A Facility          
Financing activities:          
Repayment of Term loan A facility     $ (6,563) $ (5,625)